Indication

Ankylosing spondylitis

Ankylosing spondylitis is a chronic, systemic inflammatory arthritis classified within the spondyloarthritis family that primarily targets the axial skeleton, particularly the sacroiliac joints and spine. Read more about Ankylosing spondylitis

715 drugs 254 manufacturers

Advertisement

Drugs that treat it

Common Ankylosing spondylitis therapies.

Showing 586–594 of 715 drugs

INDOMETHACIN

NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND SALICYLATES·GOUT·+9
ZYDUS USA-NOVAP

DEXAMETHASONE

GLUCOCORTICOSTEROIDS·DISSEMINATED TUBERCULOSIS·+61
Amneal Pharmaceuticals

HYDROCORTISONE

GLUCOCORTICOSTEROIDS·TRICHINOSIS·+51
Amneal Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Ankylosing spondylitis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Ankylosing spondylitis.

Ankylosing spondylitis is a chronic, systemic inflammatory arthritis classified within the spondyloarthritis family that primarily targets the axial skeleton, particularly the sacroiliac joints and spine.

The condition characteristically manifests in late adolescence or early adulthood, exhibiting a strong genetic association with human leukocyte antigen B27 (HLA-B27).

Pathophysiologically driven by immune-mediated enthesitis and osteitis, it causes inflammatory back pain, progressive spinal stiffness, and peripheral joint involvement.

Over time, persistent chronic inflammation can stimulate pathologic new bone formation, syndesmophyte bridging, and eventual spinal ankylosis, leading to marked loss of mobility and structural postural changes.

Personalize your experience

Follow Ankylosing spondylitis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it